Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Cervical Adenocarcinoma 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Salpingo-oophorectomy × Gynecologic × Clear all
NCT01048853 2026-01-07

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

M.D. Anderson Cancer Center

Phase NA Terminated
137 enrolled 15 charts
Gynecologic

Cervical Adenocarcinoma

NCT06752135 2024-12-30

HRCC1

Azienda Policlinico Umberto I

Terminated
97 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03382574 2022-06-14

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Terminated
2 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡